Detalhe da pesquisa
1.
DNA damage remodels the MITF interactome to increase melanoma genomic instability.
Genes Dev
; 38(1-2): 70-94, 2024 Feb 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38316520
2.
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance.
Nature
; 623(7989): 1053-1061, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37844613
3.
Genomic correlates of clinical outcome in advanced prostate cancer.
Proc Natl Acad Sci U S A
; 116(23): 11428-11436, 2019 06 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31061129
4.
Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study.
Lancet Oncol
; 21(11): 1478-1488, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33128873
5.
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.
Lancet Oncol
; 21(1): 162-174, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31806540
6.
Genetic Analysis of Circulating Tumour Cells.
Recent Results Cancer Res
; 215: 57-76, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-31605223
7.
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.
N Engl J Med
; 375(5): 443-53, 2016 Aug 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-27433846
8.
Detection of circulating tumour cell clusters in human glioblastoma.
Br J Cancer
; 119(4): 487-491, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30065256
9.
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
N Engl J Med
; 373(18): 1697-708, 2015 Oct 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-26510020
10.
Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions.
Oncology
; 90(5): 280-8, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27082424
11.
An orchestrated program regulating secretory pathway genes and cargos by the transmembrane transcription factor CREB-H.
Traffic
; 14(4): 382-98, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23279168
12.
Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial.
Eur J Cancer
; 205: 114103, 2024 May 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38729054
13.
Thio-2 inhibits key signaling pathways required for the development and progression of castration resistant prostate cancer.
Mol Cancer Ther
; 2024 Feb 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38412481
14.
Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study.
Lancet Oncol
; 13(11): 1114-24, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23059046
15.
Multiparametric bone MRI targeting aides lesion selection for CT-guided sclerotic bone biopsies in metastatic castrate resistant prostate cancer.
Cancer Imaging
; 23(1): 121, 2023 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38102655
16.
DNA damage-induced interaction between a lineage addiction oncogenic transcription factor and the MRN complex shapes a tissue-specific DNA Damage Response and cancer predisposition.
bioRxiv
; 2023 Apr 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37131595
17.
Critical role of antioxidant programs in enzalutamide-resistant prostate cancer.
Oncogene
; 42(30): 2347-2359, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37355762
18.
Germline ATM Mutations Detected by Somatic DNA Sequencing in Lethal Prostate Cancer.
Eur Urol Open Sci
; 52: 72-78, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37284046
19.
B7-H3 as a Therapeutic Target in Advanced Prostate Cancer.
Eur Urol
; 83(3): 224-238, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36114082
20.
Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence-Enabled Studies of Acute Phosphoproteomic Changes.
Mol Cancer Ther
; 21(6): 1020-1029, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35368084